Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU
Links shared publicly online about this topic.
- 970total visits
Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU
View full resource at medicalnewstoday.com
Tags: Neurology, PKU, Pharma, Phase 2 Clinical Trial
Most Recently Shared on August 5, 2010 at 9:05 pm By:
Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU http://mnt.to/3H29 #genetics
Also Shared By:
Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU - QualityPoint Technologies
qualitypointtech.net — “BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010. Key highlights of the study: -- 23 adult patients have been enrolled in the study, and patients have been followed for a median of 111 days. The ” View full resource at qualitypointtech.net
Most Recently Shared on August 5, 2010 at 3:33 pm By:
Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU: BioMarin Pharmaceu... http://bit.ly/aZq8S6
Advertisement
MNT Endocrinology
@mnt_endocrine
Encouraging Preliminary Safety And Efficacy Trends In Phase 2 Clinical Study Of PEG-PAL In PKU http://mnt.to/3H29 #endocrinology
1 year ago...